Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TBK1 | Q9UHD2 | 8/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8225144 | 0.90 | IGF1R (0.40) | TBK1CYP3A4CYP2D6 | |
| SCHEMBL13003906 | 0.81 | CYP3A4 (0.54) | CYP3A4 | |
| SCHEMBL13060188 | 0.78 | GSK3B (0.48) | TBK1 | |
| SCHEMBL13390971 | 0.71 | ACKR3 (0.42) | TBK1CYP3A4 | |
| SCHEMBL12533226 | 0.71 | ACKR3 (0.43) | TBK1CYP3A4 | |
| SCHEMBL8223229 | 0.71 | TBK1 (0.51) | TBK1 | |
| SCHEMBL12533228 | 0.71 | ACKR3 (0.42) | TBK1CYP3A4 | |
| SCHEMBL13060396 | 0.69 | ACKR3 (0.45) | TBK1 | |
| SCHEMBL8420505 | 0.69 | CYP3A4 (0.55) | CYP3A4 | |
| SCHEMBL8230768 | 0.69 | POLB (0.42) | TBK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7846946-B2 | Heteroatom-linked substituted piperidines and derivatives thereof useful as histamine H3 antagonists | SCHERING PLOUGH CORPORATION (US) | 2010-12-07 | — | — | US | disclosed |
| US-20090286830-A1 | HETEROATOM-LINKED SUBSTITUTED PIPERIDINES AND DERIVATIVES THEREOF USEFUL AS HISTAMINE H3 ANTAGONISTS | SCHERING CORPORATION | 2009-11-19 | — | — | US | disclosed |
| US-20070142369-A1 | Combination of an H3 antagonist/inverse agonist and an appetite suppressant | SCHERING CORPORATION | 2007-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070142369-A1 | Combination of an H3 antagonist/inverse agonist and an appetite suppressant | CNR2, GPR119, GLP1R | TBK1 2533/4885CYP3A4 1140/4885CYP2D6 1688/4885 |
| US-20090286830-A1 | HETEROATOM-LINKED SUBSTITUTED PIPERIDINES AND DERIVATIVES THEREOF USEFUL AS HISTAMINE H3 ANTAGONISTS | HRH3, HRH4, CHRM2 | TBK1 4090/4885CYP3A4 1177/4885CYP2D6 891/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.